首页> 美国卫生研究院文献>Blood Advances >Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma not otherwise specified
【2h】

Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma not otherwise specified

机译:蛋白质组学分析可鉴定外周T细胞淋巴瘤患者的预后指标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) constitutes a heterogeneous category of lymphomas, which do not fit into any of the specifically defined T-cell lymphoma entities. Both the pathogenesis and tumor biology in PTCL-NOS are poorly understood. Protein expression in pretherapeutic PTCL-NOS tumors was analyzed by proteomics. Differentially expressed proteins were compared in 3 distinct scenarios: (A) PTCL-NOS tumor tissue (n = 18) vs benign lymphoid tissue (n = 8), (B) clusters defined by principal component analysis (PCA), and (C) tumors from patients with chemosensitive vs refractory PTCL-NOS. Selected differentially expressed proteins identified by proteomics were correlated with clinico-pathological features and outcome in a larger cohort of patients with PTCL-NOS (n = 87) by immunohistochemistry (IHC). Most proteins with altered expression were identified comparing PTCL-NOS vs benign lymphoid tissue. PCA of the protein profile defined 3 distinct clusters. All benign samples clustered together, whereas PTCL-NOS tumors separated into 2 clusters with different patient overall survival rates (P = .001). Differentially expressed proteins reflected large biological diversity among PTCL-NOS, particularly associated with alterations of “immunological” pathways. The 2 PTCL-NOS subclusters defined by PCA showed disturbance of “stress-related” and “protein metabolic” pathways. α-Enolase 1 (ENO1) was found differentially expressed in all 3 analyses, and high intratumoral ENO1 expression evaluated by IHC correlated with poor outcome (hazard ratio, 2.09; 95% confidence interval, 1.17-3.73; P = .013). High expression of triosephosphate isomerase (TPI1) also showed a tendency to correlate with poor survival (P = .057). In conclusion, proteomic profiling of PTCL-NOS provided evidence of markedly altered protein expression and identified ENO1 as a novel potential prognostic marker.
机译:周围T细胞淋巴瘤(未另作说明)(PTCL-NOS)构成了异类淋巴瘤,不适合任何明确定义的T细胞淋巴瘤实体。 PTCL-NOS的发病机理和肿瘤生物学都知之甚少。通过蛋白质组学分析治疗前PTCL-NOS肿瘤中的蛋白质表达。在3种不同的情况下比较了差异表达的蛋白质:(A)PTCL-NOS肿瘤组织(n = 18)与良性淋巴组织(n = 8),(B)通过主成分分析(PCA)定义的簇,以及(C)化学敏感性或难治性PTCL-NOS患者的肿瘤。通过蛋白质组学鉴定的选定差异表达蛋白与PTCL-NOS(n = 87)的更大人群中免疫组织化学(IHC)的临床病理特征和预后相关。通过比较PTCL-NOS与良性淋巴组织,鉴定出大多数表达改变的蛋白质。蛋白质谱的PCA定义了3个不同的簇。所有良性样本均聚集在一起,而PTCL-NOS肿瘤则分成2个簇,具有不同的患者总生存率(P = .001)。差异表达的蛋白质反映了PTCL-NOS之间的巨大生物多样性,特别是与“免疫”途径的改变有关。 PCA定义的2个PTCL-NOS子类显示出“压力相关”和“蛋白质代谢”途径的紊乱。在所有3项分析中均发现α-烯醇酶1(ENO1)差异表达,通过IHC评价的肿瘤内ENO1高表达与不良预后相关(危险比,2.09; 95%置信区间,1.17-3.73; P = 0.013)。磷酸三糖异构酶(TPI1)的高表达也显示出与不良生存相关的趋势(P = .057)。总之,PTCL-NOS的蛋白质组学分析提供了蛋白质表达显着改变的证据,并将ENO1鉴定为新型潜在的预后标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号